Loading clinical trials...
Loading clinical trials...
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Dupilumab
Placebo (for Dupilumab)
Locations
101
United States
Birmingham, Alabama, United States
Fort Smith, Arkansas, United States
Rogers, Arkansas, United States
Clovis, California, United States
Lomita, California, United States
Los Angeles, California, United States
Start Date
October 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
February 1, 2016
Last Updated
November 21, 2017
NCT05391061
NCT06488742
NCT05250115
NCT04975438
NCT03563066
NCT04011215
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions